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Abstract 18 
Monitoring of Plasmodium falciparum sensitivity to antimalarial drugs in Africa is vital for 19 
malaria elimination. However, the commonly used ex-vivo/in-vitro IC50 test is inconsistent for 20 
several antimalarials, while the alternative ring-stage survival assay (RSA) for artemisinin 21 
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 2 
derivatives has not been widely adopted. Here we applied an alternative two-colour flow-22 
cytometry based parasite survival rate assay (PSRA) to detect ex-vivo antimalarial tolerance 23 
in P. falciparum isolates from The Gambia.  24 
PSRA infers parasite viability from quantifying re-invasion of uninfected cells following 3 25 
consecutive days of drug exposure (10-fold  the IC50 drug concentration of field isolates). The 26 
drug survival rate for each isolate is obtained from the slope of the growth/death curve. We 27 
obtained PSRA of 41 isolates for DHA and LUM, out of 51 infections tested by RSA against 28 
DHA. We also determined the genotypes for known drug resistance genetic loci in Pfdhfr, 29 
Pfdhps, Pfmdr, Pfcrt and Pfk13 genes.  30 
The PSRA for 41 Gambian isolates showed faster killing and lower variance by DHA 31 
compared to LUM, despite a strong correlation between both drugs. Four and three isolates 32 
were respectively tolerant to DHA and LUM, with continuous growth during drug exposure. 33 
Isolates with the PfMDR1-Y184F mutant variant had increased LUM survival though this 34 
was not statistically significant. Sulphodoxine/Pyrimethamine (SP) resistance markers were 35 
fixed, while all other antimalarial variants were prevalent in more than 50% of the 36 
population.  37 
The PSRA detected ex-vivo antimalarial tolerance in Gambian P. falciparum. This calls for 38 
its wider application and increased vigilance against resistance to ACTs in this population. 39 
Introduction 40 
There has been a substantial decline in malaria morbidity and mortality in sub-Saharan Africa 41 
over the past decade 
1
. This was mainly driven by the scale-up of control interventions such 42 
as long-lasting insecticidal nets and clinical case management with artemisinin-based 43 
combination therapy (ACT) 
1
. Currently, ACTs are used in endemic countries for the 44 
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 3 
treatment of clinical malaria, for individual chemoprevention in mass treatment campaigns 
2
. 45 
These interventions increase pressure on the parasites which could result in the emergence of 46 
resistance to both partner drugs and artemisinin-derivatives as confirmed in southeast Asia 
3,4
 47 
and delayed parasite clearance reports in Africa 
5
.  48 
Currently, the WHO recommends regular efficacy testing of the locally used antimalarials in 49 
humans, complemented by in-vitro (laboratory-based) assessment of parasite growth in 50 
response to drug exposure 
6
. Comparing the in-vitro efficacy of ACTs is complex as the 51 
components have different mechanisms of action 
5
. Moreover, most of the existing drug 52 
susceptibility assays were developed when treatment was based on monotherapies 
7,8
. The 53 
most common assays are based on the IC50 ; drug concentrations required to inhibit parasite 54 
growth by half, under a set of experimental conditions 
9,10
. This approach is sensitive to 55 
variations in drug concentrations used and inconsistency in data analysis 
11
. IC50 assays also 56 
do not assess the temporal course of parasite viability following exposure, and are not suited 57 
for artemisinin derivatives with characteristically shorter half-lives 
9
. 58 
New in-vitro methods assessing the efficacy of fast-acting drugs such as the Ring-stage 59 
Survival Assay (RSA) 
12
, Piperaquine survival assay (PSA) 
13
 and Parasite Viability Fast 60 
Assay (PVFA) 
14
 are now available. RSA and PSA determine parasite survival following 61 
drug exposure and withdrawal, while the PVFA aims at discriminating fast-acting anti-62 
malarial drugs by assessing parasite killing kinetics over time. There are still critical gaps in 63 
these assays; RSA was designed solely for fast-acting drugs and therefore cannot be used for 64 
slow-acting antimalarials with longer half-lives 
15
. The PVFA has only been used in 65 
antimalarial development for screening candidate drugs. 66 
Besides in-vitro assessment of drugs, molecular surveillance is recommended to monitor the 67 
emergence and spread of resistance by determining the proportion of isolates in a given 68 
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 4 
population with resistance associated alleles 
16,17
. While the Kelch-13 molecular markers of 69 
artemisinin resistance have not been identified in sSA 
18
, resistant alleles in PfCRT and 70 
PfMDR1 for both current and previously used drugs, including partners in ACTs, are in 71 
circulation 
19
. For instance, the use of lumefantrine in the ACT artemether-lumefantrine (AL) 72 
has been associated with an increase in copy numbers, the frequency of N86 allele, and the 73 
N86/184F/D1246 haplotype of PfMDR1 
20–25
. Additionally, Sulphodoxine/Pyrimethamine 74 
(SP) used in seasonal malaria chemoprevention (SMC) and intermittent preventive treatment 75 
in pregnancy (IPTp) select for mutant PfDHFR and PfDHPS alleles 
26
. Combining molecular 76 
surveillance with in-vitro surveillance can therefore provide an early warning signal on the 77 
emergence of drug tolerant parasites. This is critical for a parasite population that is exposed 78 
to substantial pressure by drug and vector control interventions such as in The Gambia, where 79 
malaria transmission and prevalence are low to very low. The Gambia together with 80 
neighbouring Senegal is driving for malaria elimination by deploying SMC, while mass drug 81 
treatments with ACTs are being contemplated.  82 
Therefore, the goal of this study was to evaluate a Parasite Survival-Rate Assay (PSRA) to 83 
estimate ex-vivo drug sensitivity of P. falciparum from The Gambia to the currently used 84 
ACT (AL). The PSRA mimics 3 days of exposure to an ACT, measuring parasite survival 85 
rates over this period. The assay assesses the survival and re-invasion potential of parasites 86 
following exposure to lumefantrine (LUM) and dihydroartemisinin (DHA); prototypes of 87 
slow- and fast-acting components of ACTs used in most endemic countries. The approach 88 
offers significant advantages over the standard IC50 determination assay due to its higher 89 
sensitivity in measuring parasite viability based on the production of invasive merozoites 90 
after drug exposure; an index of susceptibility or drug tolerability. 91 
Materials and Methods  92 
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 5 
Sample collection  93 
Ethical clearance for this study was obtained from the Gambia Government/MRCG Joint 94 
Ethics committee and further approved by the Gambian Ministry of Health. The study was 95 
conducted as part of a therapeutic efficacy study (TES) of AL in collaboration with the 96 
National Malaria Control Programme (NMCP) at the Brikama Health Centre (Western 97 
Gambia) in 2017. Patients were included in the study following diagnosis of P. falciparum 98 
infection with a parasite density of at least 1000/µL. An informed consent or assent was 99 
obtained from eligible patients. Two millilitres of venous blood samples were collected at 100 
day 0 of the TES into EDTA tubes and blood spots made on Whatman filter papers 101 
(Scientific Laboratory Supplies). Filter papers were air dried and stored in sealed sample bags 102 
with silica gel desiccants. Samples were transported on ice to the MRCG at LSHTM culture 103 
facility and processed within 4 hours of collection.  104 
Parasite processing for drug assays 105 
Thin blood smears were made for all samples to identify parasite lifecycle stages. For each 106 
sample, 50 µL was used to estimate parasite density using a C6 flow cytometer (BD 107 
Accuri™, BD Biosciences) after DNA staining with SYBR Green I DNA intercalating dye 108 
(Applied Biosystems). To eliminate white blood cell populations from the analysis, gating 109 
was done on the red blood cell (RBC) population only using forward and side scatter 110 
parameters followed by gating of the SYBR green 1 positive population which effectively 111 
delineates parasitized RBCs. Plasma was separated from blood cells following centrifugation 112 
for 5 minutes at 1500 rpm. An equal volume of incomplete media (RPMI 1640 (Sigma-113 
Aldrich, UK) supplemented with 35 mM HEPES (Sigma, St. Louis, MO), 24 mM NaHCO3, 114 
1 mg/l of hypoxanthine (Sigma), 5g/ml of gentamicin (Gibco-BRL)) was added to the cell 115 
pellet and layered on 6 ml of lymphoprep (Axis-Shield, UK). The layered sample was 116 
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 6 
centrifugated for 20 minutes at 2,500 rpm and leukocytes aspirated. The RBCs were washed 117 
thrice by re-suspending the pellet in incomplete media and centrifugated for 5 minutes at 118 
1,500 rpm. The washed pellet was re-suspended in growth medium: incomplete medium with 119 
0.5% Albumax (Gibco-BRL). The parasitemia was normalized to 0.5% (1000 parasites / µL) 120 
for all samples with parasitemia higher than 0.5% and 2% haematocrit using uninfected O
+ 121 
heterologous RBCs prior to PSRA and RSA. Four laboratory adapted strains were used as 122 
internal controls: 3D7, Dd2 and MRA-1239 which are sensitive to both LUM and DHA, and 123 
MRA-1241 which is sensitive to LUM but resistant to DHA.  The isolates were routinely 124 
cultured with fresh O
+
 RBCs and maintained at 2% haematocrit with growth media under 125 
standard incubation conditions of 37C, 90% N2, 5% O2, and 5% CO2. All laboratory adapted 126 
strains were synchronized twice with 5% D- sorbitol to obtain  80% ring stages prior to 127 
assay set-up. One hundred and seventy samples were obtained from Brikama Health Centre 128 
in 2017. 129 
Parasite Survival Rate Assay (PSRA) 130 
The parasite survival rate assay is based on re-invasion of surface labelled uninfected O
+
 131 
RBCs (uRBC) by merozoites emerging from ruptured schizonts that developed after drug 132 
exposure of infected samples. This was a modification of the protocol described 
14
. Here, 133 
target uRBCs were pre-labelled with the amine-reactive fluorescent dye:7-hydroxy-9H-(1,3-134 
dichloro-9, 9-dimethylacridin-2-one) succinimidyl ester (DDAO-SE; 10 μM; Invitrogen); a 135 
far-red cell dye as described 
27
. A 2% haematocrit suspension of the uRBCs in incomplete 136 
media with 10 μM DDAO-SE was made and incubated at 37C for 2 hours while shaking. 137 
The suspension was washed once, re-suspended with incomplete media and re-incubated for 138 
a further 30 minutes. DDAO-SE labelled uRBC suspension: uRBC
DDAO-SE
 were washed and 139 
reconstituted with growth media for a final haematocrit of 2%. 140 
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 7 
PSRAs were set up using laboratory isolates of  80% rings (in vitro) and field isolates 141 
within 4 hours of sample collection (ex vivo). The assay were done in triplicate for sensitivity 142 
to concentrations that were 10-fold higher than the median IC50 of the respective drugs 143 
determined in a previous study 
19
. Briefly, 100 L of parasite suspension at 0.5% parasitemia 144 
and 4% hematocrit was added to 48-well microtiter plates pre-coated with 100 L of the 145 
respective drugs at twice the target concentration [(10-fold median IC50) x 2]. This resulted in 146 
a final drug concentration of 10-fold median IC50 of DHA (8.1 nM) and LUM (398 nM) at 147 
2% haematocrit. A no-drug control, substituted with 0.1% dimethyl sulfoxide: DMSO 148 
(Sigma-Aldrich, UK) was assayed for each sample. The samples in the microtiter plates were 149 
incubated for 24-, 48- and 72- hours respectively using standard incubation conditions. Drugs 150 
were refreshed every 24 hours after washing cells by incubating twice for 5 minutes with 151 
incomplete media. Fifty microliters of the drug-free suspension was transferred to a fresh 96-152 
well microtiter plate containing 100 L of uRBCDDAO-SE (1 in 3 dilution) which was further 153 
incubated for 48 hours (Figure 1).  154 
Each sample was then washed and counterstained with 1:10,000 dilution of SYBR Green I in 155 
phosphate buffered saline (PBS). For this, 100 L of diluted stain solution was added to each 156 
assay well of the microtiter plate and incubated in the dark at room temperature with shaking 157 
for 20 minutes. Stained cells were washed twice and re-suspended with 200 L of PBS. A 158 
further 1 in 4 dilutions with PBS was done prior to flow cytometric counting using BD 159 
Accuri
TM
 C6 flow cytometer. For acquisition, the fluorescence emission peak for SYBR 160 
Green I and DDAO-SE were set at 520nm and 657nm for the green and red channels 161 
respectively. For each assay well, 100,000 events were acquired, and data analysed using the 162 
BD Accuri
TM
 C6 software.  163 
Ring-stage survival assay (RSA) 164 
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 8 
A modification of the RSA protocol 
12,28
. was carried out to assess the re-invasion potential of 165 
parasites exposed to 700nM of DHA, replacing microscopy with two-colour flow cytometry 166 
similar to the PSRA protocol above. Leukocyte depleted infected RBCs (iRBCs) were set up 167 
in duplicates at 0.5% parasitemia and 2% hematocrit. Each isolate was exposed to 700 nM of 168 
DHA and 0.1% DMSO as control for exactly 6 hours under standard incubation conditions. 169 
DHA and DMSO were then washed off using incomplete media and parasites re-suspended 170 
with drug-free growth media. Fifty microliters of this suspension was added to 100 L 171 
uRBC
DDAO-SE
 in a separate 96-well microtiter plate and both plates incubated for a further 66 172 
hours. Thin blood smears were then made and stained with Giemsa following the standard 173 
RSA protocol. Ring-stage survival rates were determined microscopically using the initial 174 
parasitemia before drug exposure (initial parasitemia: INI), DMSO control (non-exposed: 175 
NE) and DHA-exposed (DHA). Ring-stage survival was calculated for isolates with growth 176 
rate of  1% using the published formula: 177 
Percentage survival (%) = (DHA/NE) x 100 178 
The cells incubated with uRBC
DDAO-SE
 were counterstained as above with SYBR Green I and 179 
acquired using BD Accuri
TM
 C6 flow cytometer to determine parasite re-invasion rates. 180 
Genotyping of selected drug resistance loci  181 
Genotyping was done by locus specific high-resolution melt (HRM) assays with parasite 182 
DNA extracted from filter paper dried blood spots (DBS). To recover parasite DNA, DBS 183 
were punched onto 96-deep well plates, using punchers and forceps that were rinsed in 1% 184 
bleach and alpha-Q water after each sample to limit cross-contamination. For each plate, 4 185 
negative and 4 positive controls were included. Genomic DNA was manually extracted using 186 
the QIAamp® 96 DNA Blood Kit (Qiagen, Hilden, Germany) with manufacturer’s 187 
instructions. The DNA concentration of the eluates were quantified using a Nanodrop 1000 188 
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 9 
(Thermo Scientific) and stored at -20°C until use. One micromolar of gDNA of 189 
approximately 10pg-1ng/uL, was used for genotyping assays.  HRM genotyping reactions 190 
were performed for the following alleles: pfcrt C72/M74/N75/K76, pfmdr1 N86, pfmdr1 191 
Y184, pfdhps S436/A437, pfdhfr N51/C59 and pfk13 C580 on the LightCycler® 96 Real-192 
Time PCR System (Roche). The primers and probes used for PCR reactions with 2.5X 193 
LightScanner master-mix (Biofire) were as previously described 
29
. Each reaction had a final 194 
forward and reverse primer concentration of 0.05 µM and 0.2 µM respectively (asymmetric 195 
PCR) and 0.2 µM for allele specific probes. The PCR conditions and analysis method used 196 
are as previously described 
29
.  197 
Statistical analysis of drug survival rates 198 
The analysis aimed mainly at evaluating the effect of drug exposure from the magnitude of 199 
decline in growth by re-invasion with time of exposure compared to drug free controls, i.e. 200 
LUM Vs no-drug and DHA Vs no-drug. We also aimed to explore patterns of variation in 201 
response to drug exposure between isolates. To first assess the effect of time of exposure on 202 
survival (growth), the re-invasion rates were log-transformed for normality and these values 203 
were used for descriptive statistics on responses at each time-point. Linear mixed effect 204 
models were then fitted to examine the heterogeneity in drug susceptibility allowing for 205 
interaction between time and drug treatment group (LUM or DHA) with random effects on 206 
subjects. Since there were three discrete time points of measurement, an indication of 207 
potential non-linear relationship between treatment response and time, we used time as 208 
categorical variable comparing differences in effect of treatment for 48- and 72- hours against 209 
24 hours as reference. As such we could examine the effect of longer exposure. To explore 210 
the difference in susceptibility to each drug per isolate, we first obtained the drug effect from 211 
the difference between drug exposed and no-drug control at each time point. We then fitted a 212 
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 10 
linear trend across timepoints for each isolate, deriving patterns of individual growth decay 213 
slopes. These estimated slopes represent individual parasite survival (or death) rates. Based 214 
on the derived decay patterns (individual trajectories), an isolate was assigned to one of the 215 
four classes: linear decrease (---), linear increase (+++), non-linear increase/decrease (+-+) 216 
and non-linear decrease/increase (-+-). In addition, we assessed the relationship between 217 
individual trajectories and their corresponding genotypes. All analyses were performed using 218 
the R package (RStudio version 1.2.5001) and Stata 14 (StataCorp, College Station, TX, 219 
USA). A P value of <0.05 was considered significant. Other plots were explored using Prism 220 
(GraphPad Prism version 7.0a). 221 
Results 222 
Plasmodium falciparum isolates collected from patients with uncomplicated malaria cases 223 
recruited across the malaria transmission season in 2017 from Western Gambia were 224 
analysed. A total of 79 out of 170 (46.5%) isolates had a parasitemia of  0.5% and these 225 
were set up for both PSRA and RSA assays. Analysis data was obtained for 41 (52%) and 51 226 
(64.6%) samples which had a drug free ex vivo growth rate of 1% for PSRA and RSA 227 
respectively. Apart from the field isolates used in this study, the PSRA was tested against a 228 
panel of previously characterized isolates, including an artemisinin resistant parasite line: 229 
MR4-1241 with the K13 I543T mutation.  230 
Ring stage survival rates of field isolates by Microscopy and Flow cytometry 231 
Ring stage survival rates of 51 isolates were determined using conventional microscopy as 232 
per the initial RSA protocol 
12
 and modified using uRBC
DDAO-SE
 and SYBR Green I for flow 233 
cytometric analysis. Following pulse exposure to DHA, 31 isolates (61%) had surviving 234 
parasites observed by microscopy, ranging from 0.05 to 1.2% (Figure 2a). Flow cytometric 235 
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 11 
counting of re-invasion in pre-labelled uRBCs was more sensitive, showing all isolates to 236 
have post-drug exposure survival ranging from 0.14 to 1.53%. The mean survival rates 237 
determined by flow cytometric analysis was statistically higher than microscopy (P <0.0001). 238 
Despite this, there was a strong positive correlation between the two analysis methods, with 239 
R= 0.83 and p = 2.7 x 10
-14
 (Figure 2b). However, isolates with the highest ring survival rates 240 
by flow cytometry were not the same observed by microscopy.  Based on flow cytometry 241 
only, % ring survival after 6 hours of exposure to 700nM of DHA significantly correlated 242 
with parasite survival rates following PSRA analysis (R = 0.53, p = 0.00038), (figure 2c). 243 
Overall, the median cumulative rates of survival over the 72 hours of exposure was not 244 
significantly different between DHA (-0.051 to 0.029) and LUM (-0.048 to 0.037), (p = 0.35) 245 
though the responses to LUM had a wider distribution (Figure 2d).  246 
P. falciparum ex-vivo survival decreases with longer drug exposure 247 
By comparing log of survival rates between isolates with different durations of drug 248 
exposure, the overall survival declined with increased exposure time for both drugs. Whereas, 249 
there was an increasing growth trend in the drug-free group over time (Figure 3). The mean 250 
differences between treatment and control groups was always significant and increased with 251 
time as treatment groups appeared to show a marked decline in predicted survival particularly 252 
after 72 hours (Supplementary figure 1). Pairwise comparison between the drug-treated 253 
groups against drug-free group showed significant differences at all three timepoints (Table 254 
1). Using 24 hours as the reference, differences in predicted responses were seen for both 255 
DHA and LUM at 72 hours post drug exposure. At 48 hours, the differences in predicted 256 
responses were not statistically significant when compared to 24 hours. This could be due to 257 
the exponential increase in merozoite infected RBCs following a complete P. falciparum 258 
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 12 
growth cycle 
30
, potentially resulting to the high responses seen at 48 hours in the control 259 
group (Figure 3c).  260 
Distribution of PSRA sensitivities to AL 261 
We derived individual responses to each drug from fitting a linear model on the differences in 262 
predicted responses between the drug treated and control with time. These ex vivo parasite 263 
survival rates ranged from -0.051 – 0.029 for DHA and from -0.048 – 0.037 for LUM. The 264 
majority of isolates had a negative slope with consistently reducing survival with time 265 
(Figure 3a and 3b).  This was seen for 30 isolates for DHA and 35 for LUM representing 266 
73% and 85% of isolates treated respectively. Conversely, 27% (11/41) and 15% (6/41) had a 267 
net increase in growth despite 72 hours of exposure to DHA and LUM, with similar or higher 268 
predicted responses under drug conditions compared to the controls with DMSO (Figure 3a 269 
and 3b, Supplementary figure 2a and 2b). The overall response and rates of growth decline 270 
was higher for DHA compared to LUM (Figure 3c). However, the survival rates between 271 
DHA and LUM showed a strong positive correlation (R = 0.77, p = 5.4e-09), (Figure 3d). 272 
Consistent clusters of survival rate patterns to both DHA and LUM 273 
We identified four patterns of responses based on the growth vs time curve for both drugs 274 
(Figure 4a and 4b). The most common pattern was a continuous decline in survival with 275 
increase in time of exposure. This first group of isolates defined as linear decrease 276 
(designated as “---” on figure 4) represented 46 % (19/41) and 51% (21/41) of isolates tested 277 
against DHA and LUM respectively. The second group of isolates had a peak in growth at 48 278 
hours of drug exposure (“-+-”) and these represented 19.5% (8/41) and 22% (9/41) of isolates 279 
tested. The third group were isolates with consistently linear increase (“+++”)  despite drug 280 
exposure, with 9.75% (4/41) and 7.3% (3/41) identified for DHA and LUM, and the fourth 281 
pattern were isolates with the lowest survival timepoint at 48 hours (“+-+”) representing 24% 282 
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 13 
(10/41) and 20% (8/41) of isolates. These patterns did not correlate with initial parasitemia 283 
(Supplementary figure 4) or other patient demographic information. 284 
Frequencies of drug resistance alleles in western Gambia 285 
We obtained genotypes for at least 39 isolates for pfcrt C72/M74/N75/K76, pfmdr1 N86, 286 
pfmdr1 Y184, pfdhps S436/A437, pfdhfr N51/C59 and pfk13 C580 (Table 2, Figure 5). The 287 
pfcrt mutant haplotype was found in 79% of isolates with 2% of mixed infections.   93% of 288 
isolates were wildtype for pfmdr1 N86 and 5% mixed, while 57% were mutant for pfmdr1 289 
Y184 and 12% mixed. For antifolate markers, 90% of isolates had mutant variants at pfdhps 290 
S436/A437 while all isolates were mutated for pfdhfr N51/C59. We excluded the analysis for 291 
the pfdhfr alleles: IT/NC as the scoring of the melting curves were ambiguous, showing up to 292 
55% of mixed allele calls. PfK13 C580 was wildtype for all isolates. Given the almost fixed 293 
frequencies of either wildtype or mutant at these loci tested, no association with the PSRA 294 
patterns could be determined. However, for pfmdr1 codon 184, higher LUM responses were 295 
observed for isolates with the 184F mutant allele though the mean differences were not 296 
significant between these and isolates with Y184 wildtype variant (Figure 5c.ii).  297 
Discussion 298 
This study describes the ex vivo susceptibility rates of natural isolates from the Gambia, 299 
where transmission has declined, and we had seen increasing ex-vivo tolerance to 300 
Lumefantrine by IC50 as well as modest survival rates (26%) to DHA by ring-stage survival 301 
assay (RSA). These rates were obtained against DHA and LUM with a flow cytometry-based 302 
parasite survival rate assay (PSRA), with potential application to other drugs and antimalarial 303 
candidates. The potency of these drugs depend on the drug concentrations used and the length 304 
of exposure, with the assumption that cytotoxicity occurs when parasites are exposed to the 305 
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 14 
active component of the drug for a prolonged time 
31
. Here, we used drug concentrations that 306 
are 10- fold higher than the median IC50 of the respective drugs obtained from the assessment 307 
of field isolates from western Gambia in 2015 
19
. The use of 10-fold higher drug 308 
concentrations, though much lower than serum concentrations, proved to be the optimal 309 
concentration to determine the rate of kill of slow, medium and fast acting drugs. This 310 
concentration is sub-optimal, allowing for gradual effect of the drugs on the parasites 
32
. 311 
The PSRA provided several advantages over the IC50 and RSA assays; it determines the 312 
effect of drugs over 72 hours of exposure and measures both parasite growth and viability by 313 
determining re-invasion even at low parasite densities. Unlike RSA, there is no requirement 314 
for assaying early rings which can be difficult to ascertain for natural isolates from malaria 315 
patients, thereby eliminating the need for further stressing isolates by synchronizing them 316 
with sorbitol. Similar to the in vivo parasite clearance rate for determining the efficacy of 317 
artemisinin derivatives 
33
, the PSRA determines clearance rates from the rate of ex vivo 318 
inhibition of growth over 72 hours of drug exposure. This duration of exposure allows rings 319 
that emerge from tolerant isolates over the first cycle (48 hours) to experience another round 320 
of drug exposure for 24 hours, followed by recovery in drug free medium. The overall 321 
outcome is the kinetics of parasite killing by the test drug over 72 hours. This assay is 322 
therefore a variant of the PVFA 
14,32
. Like PVFA, the PSRA does not assess parasite 323 
metabolic activity or other parasite molecules to quantify survival or death indirectly 
14
. It 324 
quantifies viability from a direct count of viable merozoites that emerge from drug-exposed 325 
schizonts and invade pre-stained uninfected RBCs: uRBC
DDAO-SE
.  Flow cytometry provided 326 
increased sensitivity by individually counting cells and distinguishing new autologous and 327 
heterologous infected cells. With a 2 to 1 ratio of RBC
DDAO-SE
 to non-labelled RBCs, higher 328 
numbers of pre-labelled RBCs are present, skewing re-invasion to occur in these cells. As 329 
merozoites emerge after drug exposure, active re-invasion is proof of viability. This gives a 330 
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 15 
good estimate of the number of parasites that survive following drug exposure. The rate of 331 
death is therefore intrinsic to the level of drug tolerance by each isolate. Autologous re-332 
invasion of unlabelled RBCs are excluded from the analysis as they cannot be differentiated 333 
from dead and arrested cells. Unlike RSA, the PSRA uses a much lower concentration of 334 
drug but potent enough to kill isolates and to induce the delayed clearance phenotype in RSA 335 
control isolate (MRA-1241). Hence, there was a high positive correlation between PSRA and 336 
flow-cytometry modified RSA. With strong correlation with microscopy but improved 337 
throughput, flow cytometry-based RSA and PSRA should allow for robust detection of 338 
emerging drug tolerance in natural isolates. Future and wider application of this method is 339 
warranted in Africa where drug pressure is substantial. This is the case for The Gambia 340 
where the artemisinin-based combination therapy AL is used as first line treatment and other 341 
ACTs are being considered for mass administration after several clinical trials.  342 
Most of the isolates tested by PSRA in The Gambia had decreasing parasite survival with 343 
increasing days of exposure to drugs. However, four isolates exposed to DHA and three to 344 
LUM continued to grow and were considered potentially tolerant with one isolate surviving 345 
in the presence of both drugs. More isolates would have been classified as tolerant if all those 346 
that showed a rebound of growth at 72 hours were included. These suggest a state of reduced 347 
drug sensitivity, allowing parasite growth and re-invasion to occur in the presence of sub-348 
lethal drug concentrations 
34
. The six surviving  isolates could be on a path towards a 349 
persistent state of drug insensitivity that may result in resistance 
35
 and should be closely 350 
monitored. Extending the assay time to 96 hours could also reveal clearer response profiles 351 
for the isolates with non-linear responses over the 72-hour period. Importantly, the weak 352 
correlation between initial patient parasitemia and parasite response suggests that the 353 
responses seen are not driven by the rate at which parasites grew in the patient (in vivo). Most 354 
isolates had similar response patterns for both drugs and their survival rates correlated 355 
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positively. This could be an indication of common mechanisms that enable survival to several 356 
drugs, a factor that could lead to multidrug resistance. Multidrug resistance to artemisinin 357 
derivatives and partners has been confirmed in South East Asia 
36
. We have already shown in 358 
The Gambia a consistent increase of LUM tolerance between 2012 and 2015 
19
. In the same 359 
study, 26% of the isolate in the 2015 population from western Gambia showed viable 360 
parasites by microscopy-based RSA for DHA. The presence of surviving parasites in this 361 
current study though at different proportions with both assays, suggests sustained low level of 362 
DHA tolerance and requires further investigation. These parasites survived and replicated in 363 
high concentration and prolonged length of DHA pressure with RSA and PSRA respectively. 364 
Malaria transmission in western Gambia has reduced drastically in the last decade, with 365 
prevalence of infection lower than 5% overall and 1% for children under 5 years of age. 366 
Despite this, various ACTs remain widely available and accessible through private and public 367 
vendors. While it is officially required that ACTs should be prescribed only upon a positive 368 
malaria diagnosis, this is hardly sustained given regular short supplies of Rapid Diagnostic 369 
Test kits. We can therefore speculate that the emergence of tolerant parasites is being driven 370 
by high drug pressure against low transmission which is hypothesized to be one of the main 371 
drivers in the emergence of antimalarial drug resistance in South East Asia. This calls for 372 
improved vigilance across Africa as elimination programs are implemented. ACT resistance 373 
has been shown to emerge on a backbone of known drug resistance including Pfmdr1 and 374 
Pfcrt selected by LUM. The WHO recommends surveillance for known and emerging 375 
markers of resistance in natural populations.  376 
We genotyped the isolates assayed for alleles at Pfmdr1, Pfcrt, Pfdhfr, Pfdhps and Pfk13 loci 377 
that have been implicated in quinoline, antifolate or artemisinin resistance. We found high 378 
levels of resistance loci against the antifolates, an expected result given the use of SP by 379 
SMC and IPTp. We also found high levels of Pfmdr1 N86, the wild type allele selected by 380 
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LUM, a result aligning with what we had shown before for this population 
19
. On the 381 
contrary, the Pfcrt 72-76 mutant haplotype was in over 80% of isolates, indicating continuous 382 
selection by chloroquine. Chloroquine had been withdrawn for treatment of malaria raising 383 
the question as to which drugs are driving selection at Pfcrt but not Pfmdr1 
37
. Selection of 384 
Pfcrt may be driven by amodiaquine which is available in combination with artesunate 385 
accessible from private vendors in The Gambia and is the ACT of choice in neighbouring 386 
Senegal with whom there is significant human migration. We expect to gain more insights on 387 
this considering current extensive temporal and spatial genome sequencing for these parasite 388 
population. With the high levels of mutant or wild alleles at drug resistant genes, an analysis 389 
of genetic association for the four different parasite PSRA profiles was not possible. 390 
However, higher survival rates against lumefantrine were seen for isolates with the mutant 391 
variant at Pfmdr1 184F though this was not significantly different from the distribution of 392 
rates in isolates with wild alleles. We assume that the responses observed for samples 393 
carrying multiple strains is a combined effect of the different strains present and the six 394 
isolates that survived following exposure to either of the two drugs have specific molecular 395 
signatures influencing their phenotypes which should be further investigated. Despite the 396 
number of isolates showing growth after 72 hours of exposure to DHA, no mutant alleles of 397 
Pfk13 C580 were found in the population. Artemisinin associated Kelch13 variants are rare in 398 
African populations but high frequencies of other non-synonymous SNPs on Pfk13 (kelch 399 
propeller domain) had been observed for isolates from The Gambia 
38
. These further 400 
buttresses the need for routine and in-depth surveillance of this population.  401 
This study highlights early signs of ex-vivo drug tolerance of parasites from western Gambia 402 
to the most common ACT components. These were derived by PSRA which provides a 403 
significant advancement in approaches for the determination of parasite susceptibility. A 404 
wider application of this approach across sSA to distinguish drug tolerance and resistance 405 
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will support current and future chemoprevention and chemotherapeutic strategies against 406 
malaria.  407 
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Table 1. Effect of drug exposure on predicted responses of the treatment groups (DHA, 544 
LUM, DMSO-control) and exposure times (24-, 48- and 72- hours) for P. falciparum isolates 545 
analysed by PSRA. 546 
Treatment groups Difference (95%CI) P value 
(DHA vs Control) 24h -0.68 (-0.90, -0.47)  <0.0001 
(DHA vs Control) 48h -1.03(-1.25, -0.81) <0.0001 
(DHA vs Control) 72h -1.20 (-1.42, -0.99) <0.0001 
   
(LUM vs Control) 24h -0.31 (-0.52, -0.09)  0.005 
(LUM vs Control) 48h -0.62(-0.84, -0.41) <0.0001 
 o
n
 O
ctober 13, 2020 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 24 
(LUM vs Control) 72h -0.99 (-1.21, -0.77) <0.0001 
   
(48h vs 24h) Control 0.25 (0.01, 0.48) 0.04 
(48h vs 24h) DHA -0.10 (-0.33, 0.13) 0.39 
(48h vs 24h) LUM 0.07 (-0.30, 0.16) 0.57 
   
(72h vs 24h) Control 0.14 (-0.13, 0.42) 0.31 
(72h vs 24h) DHA -0.38 (-0.65, -0.10) 0.007 
(72h vs 24h) LUM -0.54 (-0.81, -0.27) 0.0001 
*24h = 24 hours; 48h = 48 hours; 72h = 72 hours; DHA = Dihydroartemisinin 
treatment; LUM = Lumefantrine treatment; Control: DMSO treatment. 
Values in bold are significant P values determined by pairwise comparisons 
Table 2. Allele frequencies of drug resistance genes for 41 parasite isolates with drug 547 
phenotypic data (PSRA and RSA). 548 
Gene Alleles Codons  Frequency 
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pfcrt C72, M74, N75, K76 CMNK (wildtype) 0.17 
CIET (mutant) 0.79 
CMNK/CIET (mixed) 0.02 
pfmdr1 N86 N (wildtype) 0.93 
Y (mutant) 0 
N/Y (mixed) 0.05 
Y184 Y (wildtype) 0.29 
F (mutant) 0.57 
Y/F (mixed) 0.12 
pfdhps S436/A437 SA (wildtype) 0.02 
SG (mutant) 0.88 
FG (mutant) 0.02 
SA/SG (mixed) 0.05 
FG/SA/SG (mixed) 0.02 
Pfdhfr 
 
 
 
N51/C59 NC (wildtype) 0 
IR (mutant) 0.26 
IT/NC (mixed) - 
IR/NR (mixed) 0.12 
NR/NC (mixed) 0.02 
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Figure 1.  549 
Schematic representation of ex vivo parasite survival rate assay. (1) iRBCs at 0.5% 550 
parasitemia and 2% haematocrit are incubated with 10-fold median IC50s of 551 
Dihydroartemisinin and Lumefantrine for 24-, 48- and 72-hour time-points. (2) uRBCs are 552 
labelled with the intracellular dye: DDAO-SE (uRBC
DDAO-SE
). (3) Drugs are washed off from 553 
step 1 every 24 hours, aliquots taken, and drugs replenished. (4) Post-exposure drug free 554 
aliquots are incubated with 2 x uRBC
DDAO-SE
 for a further 48 hours. (5,6) These are then 555 
counterstained with SYBR Green I for flow cytometric analysis where 100,000 cells are 556 
acquired (7) and double positive stained cells analysed. 557 
Figure 2. (a) Percentage ring survival of 51 isolates using conventional microscopy to assess 558 
viable parasites and flow cytometry to assess the number of re-invaded parasites following 559 
pulse exposure and withdrawal of DHA with RSA. Each point on the plot represents an 560 
isolate. The median survival rates of the isolates for each method are shown as the red broken 561 
lines. T-test statistics gave a P value of <0.0001 using Wilcoxon rank sum test. (b) 562 
Correlation analysis of percentage ring survival using flow cytometry and microscopy with a 563 
Pearson correlation coefficient of R = 0.83 and p = <0.0001 and (c) correlation analysis of 564 
percentage ring survival using RSA and parasite survival rates using PSRA analysis. Pearson 565 
pfk13 C580 C (wildtype) 1 
  Y (mutant) 0 
pfcrt = P. falciparum chloroquine resistance transporter; pfmdr1 = P. falciparum multidrug 
resistance gene 1; pfdhps = P. falciparum dihydropteroate synthase; pfdhfr = P. falciparum 
dihydrofolate reductase; pfk13= P. falciparum kelch 13 
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correlation coefficient gave an R value of 0.53 and a p value of 0.00036. (d) Distribution of 566 
the parasite survival rates of 41 isolates treated with DHA and LUM at 3 timepoints over 72 567 
hours with PSRA . Each point shows the rate at which each isolate survives following drug 568 
exposure with reference to DMSO-treated control. The red dotted lines are the median 569 
survival rates for both drug treatments with p = 0.35. P value of <0.05 represents statistical 570 
significance. All ex vivo assays were performed in triplicates. 571 
Figure 3. Individual trajectories of 41 isolates following exposure to (a) DHA and (b) LUM 572 
relative to DMSO treated control at 24-, 48-, and 72- hour timepoints. Linear mixed effect 573 
model was used, and a linear trend fitted for each isolate across timepoints. The blue and red 574 
dotted lines show the isolates with decreasing and increasing responses over time 575 
respectively. The thick blue and red lines represent the mean log response of isolates with 576 
decreasing and increasing responses respectively. (c) Mean predicted parasite responses of all 577 
isolates following exposure to DHA (red broken line), LUM (blue broken line) and DMSO 578 
control (grey broken line) with the SEM shown as bars. (d) Correlation between parasite 579 
survival rates of isolates treated with DHA and LUM with R = 0.77 and p < 0.001. All ex 580 
vivo assays were performed in triplicates. 581 
Figure 4. Grouped profiles of 41 isolates following exposure to DHA and LUM at 24, 48 and 582 
72 hours with PSRA. Each point in the individual plots represent the difference between the 583 
predicted response of the (a) DHA treated and control and (b) LUM treated and control. The 584 
connecting lines give an indication of the response pattern of each isolate.  The isolates are 585 
grouped based on their response profiles. (i) linear decrease (---), (ii) non-linear decrease/ 586 
increase (-+-), (iii) linear increase (+++), (iv) non-linear increase/decrease (+-+). 587 
Figure 5. (a) Allele frequencies of 41 field isolates for the drug resistant genes: pfcrt 588 
C72/M74/N75/K76, pfmdr1 N86, pfmdr1 Y184, pfdhps S436/A437 and pfk13 C580. Parasite 589 
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survival rates of (b) DHA and (c) LUM for isolates with wildtype, mutant and mixed alleles 590 
for pfcrt C72/M74/N75/K76, pfmdr1 Y184 and pfdhps S436/A437. Each point in the graphs 591 
represent the parasite survival rate of an isolate. The broken red lines indicate the median 592 
survival rates of the isolates with the same alleles.  593 
List of abbreviations 594 
ACT  artemisinin combination therapy 595 
AL  artemether lumefantrine  596 
DBS  dried blood spots 597 
DHA  dihydroartemisinin 598 
DMSO  dimethyl sulfoxide  599 
HRM  high resolution melting 600 
IC50  50% inhibitory concentration 601 
IPTp   intermittent preventive treatment in pregnancy 602 
LUM  lumefantrine 603 
PBS  phosphate buffered saline  604 
PSA   piperaquine survival assay 605 
PSRA  parasite survival rate assay 606 
PVFA  parasite viability fast assay 607 
RBC  red blood cells 608 
iRBC  infected red blood cells 609 
uRBC  uninfected red blood cells 610 
RSA  ring-stage survival assay 611 
SMC  seasonal malaria chemoprevention 612 
SP  sulphodoxine/pyrimethamine 613 
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TES  therapeutic efficacy study 614 
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